Tuesday, July 21, 2026
🇺🇸 FDA

pharma · Pyruvate Kinase Deficiency · Sickle Cell Disease · AGIO

Agios Netherlands

Agios Netherlands B.V.

Agios Netherlands patent portfolio — 24 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
CAMBRIDGE, MA, NL HQ
1978 Founded
20 Employees
Public company Type
AGIO · NYSE Ticker
Company details
Status
Public
HQ
CAMBRIDGE, MA, NL
Founded
1978
Employees
20
Programs
1
Drugs
8
Patents
24
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Agios Netherlands patents

24 pharmaceutical patents indexed for Agios Netherlands. 0 expire within 24 months.

Agios Netherlands has 24 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

24 patents

Patent portfolio

  1. US 11878049

    Mitapivat therapy and modulators of cytochrome P450

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11793806

    Pyruvate kinase activators for use in therapy

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11254652

    Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11234976

    Methods of using pyruvate kinase activators

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10980788

    Therapy for treating malignancies

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10799490

    Pharmaceutical compositions of therapeutically active compounds

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10717764

    Therapeutically active compounds and their methods of use

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10653710

    Combination therapy for treating malignancies

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10632114

    Pyruvate kinase activators for use in therapy

    Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10610125

    Methods and compositions for cell-proliferation-related disorders

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10449184

    Pharmaceutical compositions of therapeutically active compounds

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10294215

    Therapeutically active compounds and their methods of use

    Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10172864

    Therapeutically active compounds and their methods of use

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10093654

    Therapeutically active compounds and their methods of use

    Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9980961

    Pyruvate kinase activators for use in therapy

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9968595

    Pharmaceutical compositions of therapeutically active compounds

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9850277

    Therapeutically active compositions and their methods of use

    Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9738625

    Therapeutically active compounds and their methods of use

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9732062

    Therapeutically active compounds and their methods of use

    Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9682080

    Pyruvate kinase activators for use in therapy

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9579324

    Therapeutically active compounds and their methods of use

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9512107

    Therapeutically active compositions and their methods of use

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9474779

    Therapeutically active compositions and their methods of use

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9193701

    Pyruvate kinase activators for use in therapy

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Agios Netherlands have?

24 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Agios Netherlands patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.